Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure greater than
20 mm Hg and classified into five different groups sharing similar pathophysiologic …

Background Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for
inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However …

Background Treprostinil, a prostacyclin analogue, is effective for the treatment of pulmonary
arterial hypertension. However, information is scarce regarding treprostinil for treatment of …

Riociguat is the treatment of choice for inoperable patients with chronic thromboembolic
pulmonary hypertension (CTEPH). We addressed here whether additional balloon …

ISHLT members have recognized the importance of a consensus statement on the
evaluation and management of patients with chronic thromboembolic pulmonary …

Balloon pulmonary angioplasty (BPA) is an emerging treatment option for patients with
chronic thromboembolic pulmonary hypertension (CTEPH) who have inoperable …

Background While current guidelines require lung ventilation-perfusion (V/Q) scanning as
the first step to diagnose chronic pulmonary embolism in pulmonary hypertension (PH), its …

Background The combination of riociguat and interventional balloon pulmonary angioplasty
(BPA) is currently used to treat patients with inoperable chronic thromboembolic pulmonary …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but feared long‐term
complication of acute pulmonary embolism (PE), although CTEPH may occur in patients with …